The UK and US have finalized a significant trade agreement that will keep zero levies on British drug products going into the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to raise expenditure on drugs through the public health system. This move secures that duties on these vital exports will remain at nothing for a timeframe of 36 months.
This development comes after previous threats to dramatically increase duties on patented drug imports, with increases discussed up to one hundred percent.
"This agreement with the UK bolsters the global environment for new treatments and brings long-overdue balance to American-British pharmaceutical trade," a release declared.
Commercial Importance
Drugs represent one of the UK's largest goods shipped to the US, which is easily the primary destination for major companies like GSK and AstraZeneca.
Export figures indicate that in the year to the end of September, the UK shipped medicines totaling £11.1bn to the US. This value accounted for a significant portion of all goods exports in that span.
"This guarantee safeguards jobs, increases capital expenditure and facilitates the UK to emerge as a global hub for biotech and pharma," a minister remarked.
Specific UK Commitments
The deal involves several key pledges from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it deems new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a target to increase total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The sum manufacturers must refund to the NHS to control costs will be limited at 15%. In the past, repayments topped 20%.
Industry Background
This agreement takes place against a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
These tensions were exacerbated by assertions that US patients were charged several times more for the identical medicines than people in the UK and Europe.
Recently, several large manufacturing plans in the UK have been paused or cancelled, while major expansions have been announced toward American operations.
A senior figure stated that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had declined as a proportion of its resources over the past decade.
